Peroxisome proliferator-activated receptor δ and gastric cancer (review)

Oncology Reports

Volumn 22, Issue 3, 2009, Pages 451-457

  Wu, Chung W ^a   Yu, Jun ^a   Sung, Joseph J Y ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

COX 2; Gastric cancer; IL 1 ; NF B; PPAR ; Wnt pathway

Indexed keywords

[2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; [4 [2 (3 FLUORO 4 TRIFLUOROMETHYLPHENYL) 4 METHYL 5 THIAZOLYLMETHYLTHIO] 2 METHYLPHENOXY]ACETIC ACID; BETA CATENIN; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; T CELL FACTOR PROTEIN; WNT PROTEIN; DNA BINDING PROTEIN; TCF4 PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

APOPTOSIS; CANCER RISK; CELL DIFFERENTIATION; CELL PROLIFERATION; COLON POLYP; DRUG MECHANISM; DRUG TARGETING; FAMILY HISTORY; FOOD INTAKE; HELICOBACTER INFECTION; HUMAN; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RECTUM POLYP; REVIEW; SMOKING; STOMACH CANCER; STOMACH CARCINOGENESIS; TISSUE DISTRIBUTION; ANIMAL; PHYSIOLOGY; STOMACH TUMOR;

ANIMALS; CYCLOOXYGENASE 2; DNA-BINDING PROTEINS; HUMANS; INTERLEUKIN-1BETA; NF-KAPPA B; PPAR DELTA; STOMACH NEOPLASMS; TRANSCRIPTION FACTORS; WNT PROTEINS;

EID: 70349316861     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000456     Document Type: Review

References (71)

1. Crew KD and Neugut AI: Epidemiology of gastric cancer. World J Gastroenterol 12: 354-362, 2006.
2. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005.
3. Lochhead P and El-Omar EM: Gastric cancer. Br Med Bull (In press).
4. Desvergne B and Wahli W: Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 20: 649-688, 1999.
5. Evans RM, Barish GD and Wang YX: PPARs and the complex journey to obesity. Nat Med 10: 355-361, 2004.
6. Issemann I and Green S: Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347: 645-650, 1990.
7. Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM and Evans RM: 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 83: 803-812, 1995.
8. Tan GD, Fielding BA, Currie JM, et al: The effects of rosiglitazone on fatty acid and triglyceride metabolism in type 2 diabetes. Diabetologia 48: 83-95, 2005.
9. Peters JM, Lee SS, Li W, et al: Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor beta(delta). Mol Cell Biol 20: 5119-5128, 2000.
10. Barak Y, Liao D, He W, et al: Effects of peroxisome proliferator-activated receptor delta on placentation, adiposity and colorectal cancer. Proc Natl Acad Sci USA 99: 303-308, 2002.
11. Cheng L, Ding G, Qin Q, et al: Cardiomyocyte-restricted peroxisome proliferator-activated receptor-delta deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy. Nat Med 10: 1245-1250, 2004.
12. Lee CH, Olson P, Hevener A, et al: PPARdelta regulates glucose metabolism and insulin sensitivity. Proc Natl Acad Sci USA 103: 3444-3449, 2006.
13. Wang YX, Zhang CL, Yu RT, et al: Regulation of muscle fiber type and running endurance by PPARdelta. PLoS Biol 2: E294, 2004.
14. Lee CH, Chawla A, Urbiztondo N, et al: Transcriptional repression of atherogenic inflammation: modulation by PPARdelta. Science 302: 453-457, 2003.
15. Toney LM, Cattoretti G, Graf JA, et al: BCL-6 regulates chemokine gene transcription in macrophages. Nat Immunol 1: 214-220, 2000.
16. Ravaux L, Denoyelle C, Monne C, Limon I, Raymondjean M and El Hadri K: Inhibition of interleukin-1beta-induced group IIA secretory phospholipase A2 expression by peroxisome proliferator-activated receptors (PPARs) in rat vascular smooth muscle cells: cooperation between PPARbeta and the protooncogene BCL-6. Mol Cell Biol 27: 8374-8387, 2007.
17. Xu HE, Lambert MH, Montana VG, et al: Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Mol Cell 3: 397-403, 1999.
18. Forman BM, Chen J and Evans RM: Hypolipidemic drugs, polyunsaturated fatty acids and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci USA 94: 4312-4317, 1997.
19. Yu K, Bayona W, Kallen CB, et al: Differential activation of peroxisome proliferator-activated receptors by eicosanoids. J Biol Chem 270: 23975-23983, 1995.
20. Krey G, Braissant O, L'Horset F, et al: Fatty acids, eicosanoids and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol Endocrinol 11: 779-791, 1997.
21. Chawla A, Lee CH, Barak Y, et al: PPARdelta is a very low-density lipoprotein sensor in macrophages. Proc Natl Acad Sci USA 100: 1268-1273, 2003.
22. Barish GD, Narkar VA and Evans RM: PPAR delta: a dagger in the heart of the metabolic syndrome. J Clin Invest 116: 590-597, 2006.
23. Kim DJ, Akiyama TE, Harman FS, et al: Peroxisome proliferator-activated receptor beta (delta)-dependent regulation of ubiquitin C expression contributes to attenuation of skin carcinogenesis. J Biol Chem 279: 23719-23727, 2004.
24. Fukumoto K, Yano Y, Virgona N, et al: Peroxisome proliferator-activated receptor delta as a molecular target to regulate lung cancer cell growth. FEBS Lett 579: 3829-3836, 2005.
25. Harman FS, Nicol CJ, Marin HE, Ward JM, Gonzalez FJ and Peters JM: Peroxisome proliferator-activated receptor-delta attenuates colon carcinogenesis. Nat Med 10: 481-483, 2004.
26. Kim DJ, Murray IA, Burns AM, Gonzalez FJ, Perdew GH and Peters JM: Peroxisome proliferator-activated receptor-beta/delta inhibits epidermal cell proliferation by down-regulation of kinase activity. J Biol Chem 280: 9519-9527, 2005.
27. Yin Y, Russell RG, Dettin LE, et al: Peroxisome proliferator-activated receptor delta and gamma agonists differentially alter tumor differentiation and progression during mammary carcinogenesis. Cancer Res 65: 3950-3957, 2005.
28. Stephen RL, Gustafsson MC, Jarvis M, et al: Activation of peroxisome proliferator-activated receptor delta stimulates the proliferation of human breast and prostate cancer cell lines. Cancer Res 64: 3162-3170, 2004.
29. Glinghammar B, Skogsberg J, Hamsten A and Ehrenborg E: PPARdelta activation induces COX-2 gene expression and cell proliferation in human hepatocellular carcinoma cells. Biochem Biophys Res Commun 308: 361-368, 2003.
30. Xu L, Han C, Lim K and Wu T: Cross-talk between peroxisome proliferator-activated receptor delta and cytosolic phospholipase A(2)alpha/cyclooxygenase-2/prostaglandin E(2) signaling pathways in human hepatocellular carcinoma cells. Cancer Res 66: 11859-11868, 2006.
31. Gupta RA, Wang D, Katkuri S, Wang H, Dey SK and DuBois RN: Activation of nuclear hormone receptor peroxisome proliferator-activated receptor-delta accelerates intestinal adenoma growth. Nat Med 10: 245-247, 2004.
32. Shureiqi I, Jiang W, Zuo X, et al: The 15-lipoxygenase-1 product 13-S-hydroxyoctadecadienoic acid down-regulates PPAR-delta to induce apoptosis in colorectal cancer cells. Proc Natl Acad Sci USA 100: 9968-9973, 2003.
33. Park BH, Vogelstein B and Kinzler KW: Genetic disruption of PPARdelta decreases the tumorigenicity of human colon cancer cells. Proc Natl Acad Sci USA 98: 2598-2603, 2001.
34. Shao J, Sheng H and DuBois RN: Peroxisome proliferator-activated receptors modulate K-Ras-mediated transformation of intestinal epithelial cells. Cancer Res 62: 3282-3288, 2002.
35. Forman D and Burley VJ: Gastric cancer: global pattern of the disease and an overview of environmental risk factors. Best Pract Res Clin Gastroenterol 20: 633-649, 2006.
36. Eslick GD: Helicobacter pylori infection causes gastric cancer? A review of the epidemiological, meta-analytic and experimental evidence. World J Gastroenterol 12: 2991-2999, 2006.
37. Prinz C, Schwendy S and Voland P: H. pylori and gastric cancer: shifting the global burden. World J Gastroenterol 12: 5458-5464, 2006.
38. Konturek PC, Konturek SJ and Brzozowski T: Gastric cancer and Helicobacter pylori infection. J Physiol Pharmacol 57 (Suppl. 3): S51-S65, 2006.
39. Udhayakumar G, Jayanthi V, Devaraj N and Devaraj H: Interaction of MUC1 with beta-catenin modulates the Wnt target gene cyclinD1 in H. pylori-induced gastric cancer. Mol Carcinog 46: 807-817, 2007.
40. Hatakeyama M and Brzozowski T: Pathogenesis of Helicobacter pylori infection. Helicobacter 11 (Suppl. 1): S14-S20, 2006.
41. Permin H and Andersen LP: Inflammation, immunity, and vaccines for Helicobacter infection. Helicobacter 10 (Suppl. 1): S21-S25, 2005.
42. Liu F, Pan K, Zhang X, et al: Genetic variants in cyclooxygenase-2: Expression and risk of gastric cancer and its precursors in a Chinese population. Gastroenterology 130: 1975-1984, 2006.
43. Langman MJ, Weil J, Wainwright P, et al: Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 343: 1075-1078, 1994.
44. Solomon SD, McMurray JJ, Pfeffer MA, et al: Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352: 1071-1080, 2005.
45. Bresalier RS, Sandler RS, Quan H, et al: Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352: 1092-1102, 2005.
46. Yu J, Leung WK, Chen J, Ebert MP, Malfertheiner P and Sung JJ: Expression of peroxisome proliferator-activated receptor delta in human gastric cancer and its response to specific COX-2 inhibitor. Cancer Lett 223: 11-17, 2005.
47. Verma IM and Stevenson J: IkappaB kinase: beginning, not the end. Proc Natl Acad Sci USA 94: 11758-11760, 1997.
48. Matsumoto Y, Marusawa H, Kinoshita K, et al: Helicobacter pylori infection triggers aberrant expression of activation-induced cytidine deaminase in gastric epithelium. Nat Med 13: 470-476, 2007.
49. Rival Y, Beneteau N, Taillandier T, et al: PPARalpha and PPARdelta activators inhibit cytokine-induced nuclear translocation of NF-kappaB and expression of VCAM-1 in EAhy926 endothelial cells. Eur J Pharmacol 435: 143-151, 2002.
50. Shan W, Nicol CJ, Ito S, et al: Peroxisome proliferator-activated receptor-beta/delta protects against chemically induced liver toxicity in mice. Hepatology 47: 225-235, 2008.
51. Planavila A, Rodriguez-Calvo R, Jove M, et al: Peroxisome proliferator-activated receptor beta/delta activation inhibits hypertrophy in neonatal rat cardiomyocytes. Cardiovasc Res 65: 832-841, 2005.
52. Hwang IR, Kodama T, Kikuchi S, et al: Effect of interleukin 1 polymorphisms on gastric mucosal interleukin 1beta production in Helicobacter pylori infection. Gastroenterology 123: 1793-1803, 2002.
53. Zeng ZR, Hu PJ, Hu S, et al: Association of interleukin 1B gene polymorphism and gastric cancers in high and low prevalence regions in China. Gut 52: 1684-1689, 2003.
54. Steinbach G, Lynch PM, Phillips RK, et al: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342: 1946-1952, 2000.
55. Tatsuguchi A, Matsui K, Shinji Y, et al: Cyclooxygenase-2 expression correlates with angiogenesis and apoptosis in gastric cancer tissue. Hum Pathol 35: 488-495, 2004.
56. Leung WK, To KF, Go MY, et al: Cyclooxygenase-2 upregulates vascular endothelial growth factor expression and angiogenesis in human gastric carcinoma. Int J Oncol 23: 1317-1322, 2003.
57. Murata H, Kawano S, Tsuji S, et al: Cyclooxygenase-2 overexpression enhances lymphatic invasion and metastasis in human gastric carcinoma. Am J Gastroenterol 94: 451-455, 1999.
58. Hu PJ, Yu J, Zeng ZR, et al: Chemoprevention of gastric cancer by celecoxib in rats. Gut 53: 195-200, 2004.
59. Hollingshead HE, Killins RL, Borland MG, et al: Peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) ligands do not potentiate growth of human cancer cell lines. Carcinogenesis 28: 2641-2649, 2007.
60. Wang D, Wang H, Shi Q, et al: Prostaglandin E(2) promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor delta. Cancer Cell 6: 285-295, 2004.
61. Kinzler KW, Nilbert MC, Vogelstein B, et al: Identification of a gene located at chromosome 5q21 that is mutated in colorectal cancers. Science 251: 1366-1370, 1991.
62. Nishisho I, Nakamura Y, Miyoshi Y, et al: Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. Science 253: 665-669, 1991.
63. He TC, Chan TA, Vogelstein B and Kinzler KW: PPARdelta is an APC-regulated target of non-steroidal anti-inflammatory drugs. Cell 99: 335-345, 1999.
64. He TC, Sparks AB, Rago C, et al: Identification of c-MYC as a target of the APC pathway. Science 281: 1509-1512, 1998.
65. Tetsu O and McCormick F: Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398: 422-426, 1999.
66. Horii A, Nakatsuru S, Miyoshi Y, et al: The APC gene, responsible for familial adenomatous polyposis, is mutated in human gastric cancer. Cancer Res 52: 3231-3233, 1992.
67. Ebert MP, Fei G, Kahmann S, et al: Increased beta-catenin mRNA levels and mutational alterations of the APC and beta-catenin gene are present in intestinal-type gastric cancer. Carcinogenesis 23: 87-91, 2002.
68. Lee JH, Abraham SC, Kim HS, et al: Inverse relationship between APC gene mutation in gastric adenomas and development of adenocarcinoma. Am J Pathol 161: 611-618, 2002.
69. Ushijima T and Sasako M: Focus on gastric cancer. Cancer Cell 5: 121-125, 2004.
70. Tomita H, Yamada Y, Oyama T, et al: Development of gastric tumors in Apc(Min/+) mice by the activation of the beta-catenin/Tcf signaling pathway. Cancer Res 67: 4079-4087, 2007.
71. Reed KR, Sansom OJ, Hayes AJ, et al: PPARdelta status and Apc-mediated tumourigenesis in the mouse intestine. Oncogene 23: 8992-8996, 2004.